Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Clinical and Translational Medicine · 2024-04 · 14 (4)
DOI: 10.1002/ctm2.1656 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 25.04.2024. Verfasst von Jie Mei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Rep…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Organoids. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of China, Chinese Academy of Sciences, Zhejiang Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Organoid technology is an emerging and rapidly growing field that shows promise in studying organ development and screening therapeutic regimens. Although organoids have been proposed for a decade, concerns exist, including batch‐to‐batch variations, lack of the native microenvironment and clinical applicability. Main body The concept of organoids has derived patient‐derived tumour organoids (PDTOs) for personalized drug screening and new drug discovery, mitigating the risks of medication misuse. The greater the similarity between the PDTOs and the primary tumours, the more influential the model will be. Recently, ‘tumour assembloids’ inspired by cell‐coculture technology have attracted attention to complement the current PDTO technology. High‐quality PDTOs must reassemble critical components, including multiple cell types, tumour matrix, paracrine factors, angiogenesis and microorganisms. This review begins with a brief overview of the history of organoids and PDTOs, followed by the current approaches for generating PDTOs and tumour assembloids. Personalized drug screening has been practised; however, it remains unclear whether PDTOs can predict immunotherapies, including immune drugs (e.g. immune checkpoint inhibitors) and immune cells (e.g. tumour‐infiltrating lymphocyte, T cell receptor‐engineered T cell and chimeric antigen receptor‐T cell). PDTOs, as cancer avatars of the patients, can be expanded and stored to form a biobank.
Conclusion
Fundamental research and clinical trials are ongoing, and the intention is to use these models to replace animals. Pre‐clinical immunotherapy screening using PDTOs will be beneficial to cancer patients. Key Points The current PDTO models have not yet constructed key cellular and non‐cellular components. PDTOs should be expandable and editable. PDTOs are promising preclinical models for immunotherapy unless mature PDTOs can be established. PDTO biobanks with consensual standards are urgently needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Oujiang Laboratory; Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging, Wenzhou Medical University, Wenzhou, People's Republic of China.
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
- Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, People's Republic of China.
- Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, People's Republic of China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
- Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
ORCID-Profile: Jie Mei, Hui-Xiang Tian, Ji-Ye Yin, Peng-Yuan Wang
Förderung
- Ministry of Science and Technology of China
- Chinese Academy of Sciences
- Zhejiang Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
- Scientific research project of Furong laboratory of Central South University
- National Clinical Research Center for Geriatric Disorders
- Natural Science Foundation of Hunan Province
- National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases
Zitieren
APA
Mei, J., Liu, X., Tian, H. X., Chen, Y., Cao, Y., Zeng, J., Liu, Y. C., Chen, Y., Gao, Y., Yin, J. Y., & Wang, P. Y. (2024). Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy. Clinical and Translational Medicine, 14(4). https://doi.org/10.1002/ctm2.1656
Vancouver
Mei J, Liu X, Tian HX, Chen Y, Cao Y, Zeng J, et al. Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy. Clinical and Translational Medicine. 2024;14(4). doi:10.1002/ctm2.1656
BibTeX
@article{Mei2024,
author = {Mei, Jie and Liu, Xingjian and Tian, Hui-Xiang and Chen, Yixuan and Cao, Yang and Zeng, Jun and Liu, Yung-Chiang and Chen, Yaping and Gao, Yang and Yin, Ji-Ye and Wang, Peng-Yuan},
title = {Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy},
journal = {Clinical and Translational Medicine},
year = {2024},
volume = {14},
number = {4},
doi = {10.1002/ctm2.1656}
}
EUVIMED